ZyVersa reports $14.1M net loss for 2022, cash $5.9M; plans VAR 200 trial in Q4 2023

ZyVersa Therapeutics, Inc.

2024-Q1 EPS reported -$135.88 vs consensus -$3.77 ▼ miss (-3500.4%)

No revenue in 2022; net loss of $14.1M combined (up 75% from $8.1M in 2021).
Cash $5.9M as of Dec 31, 2022; expects to need additional financing to continue operations.
Completed business combination with Larkspur Health in Dec 2022; began trading on Nasdaq under ZVSA.
Plans investigator-initiated trial for VAR 200 in FSGS and up to two other renal indications in Q4 2023.
IC 100 preclinical program to complete in 2023; IND submission expected Q2 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ZyVersa Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.

Period: the fourth quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA , or “ZyVersa”), a clinical-stage specialty biopharmaceutical company developing first-in-class drug candidates for the treatment of renal and inflammatory diseases with high unmet medical needs, today provides a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-010560

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.